iPSC Clinical Trial: From Micromedicine to Macromedicine
Induced pluripotent stem cell (iPSC) technology has contributed to both micromedicine and macromedicine. This includes everything from disease modeling and drug development based on cellular and molecular analyses of individual patients to iPSC clinical trials for stratification based on cellular and molecular analyses of a cohort of patients. Importantly, it could allow for the creation of a more precise clinical trial by identifying a subset of patients with a specific disease who optimally respond to the drugs under investigation, thereby boosting success rates by pre-selecting these drug responders. DNA = deoxyribonucleic acid; iPSC-CM = induced pluripotent stem cell–derived cardiomyocyte; RNA = ribonucleic acid.